Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Active Lupus Nephritis
NCT05432531Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in lupus nephritis (LN) (2 arms), sponsored by Assiut University. Primary endpoint: Urine Albumin at 6 months. Status: unknown.
02
Drugs
baricitinib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05432531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432531.